# Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

> **NCT02929823** · PHASE2 · COMPLETED · sponsor: **Senju Pharmaceutical Co., Ltd.** · enrollment: 130 (actual)

## Conditions studied

- Corneal Epithelial Disorders

## Interventions

- **DRUG:** High Dose SJP-0035 Ophthalmic Solution
- **DRUG:** Low Dose SJP-0035 Ophthalmic Solution
- **DRUG:** Vehicle of SJP-0035 Ophthalmic solution

## Key facts

- **NCT ID:** NCT02929823
- **Lead sponsor:** Senju Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-05-03
- **Final completion:** 2017-05-03
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02929823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02929823, "Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02929823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*